Presentations
Neola Medical regularly participates in capital market days and investor events to present our progress and milestones. Below you will find recordings from recent presentations, held in either English or Swedish.
Redeye analyst Gustaf Meyer, CEO Hanna Sjöström discusses the key milestones from Neola Medical’s Q2 2026 report
In a new interview with Redeye analyst Gustaf Meyer, CEO Hanna Sjöström discusses the key milestones from Neola Medical’s Q2 2026 report. Watch the full interview here: Access additional insights from Redeye here:
Catch up on Neola Medical’s Q2 2026 progress.
In our latest report presentation, CEO Hanna Sjöström share reflections on our clinical progress, strengthened financing and sharpened strategic focus, while CFO David Folkesson presents the Q2 financial results. Watch the presentation and Q&A here
Neola – Aktiedagarna Stockholm 10 juni 2026
CEO Hanna Sjöström presented at Aktiedagarna in Stockholm on June 10, 2026, sharing an update on the company’s latest advancements following the positive safety results from Neola Medical’s first clinical pilot study in preterm born babies, provided an update on the...
CEO Hanna Sjöström presents the upcoming rights issue
In a new interview with Redeye equity analyst Gustaf Meyer, CEO Hanna Sjöström presents the upcoming rights issue accelerating the journey towards FDA approval and market launch. Watch on Vimeo
New Redeye Interview with CEO Hanna Sjöström
In a new interview with Redeye analyst Gustaf Meyer, CEO Hanna Sjöström discusses the reported positive safety results from Neola Medical’s first clinical pilot study, key insights and the next phase of clinical development. Watch the full interview here: Redeye...
Redeye Interview: Neola Medical Q4 2025 with CEO Hanna Sjöström
In a new interview with Redeye analyst Gustaf Meyer, CEO Hanna Sjöström discusses the key milestones from Neola Medical’s Q4 2025 report. Watch the full interview here: Redeye Interview Neola Medical Q4 2025 with CEO Hanna Sjöström Access additional insights from...
Neola Medical’s Q4 report presentation hosted by Investor Studios
Catch up on the highlights from Neola Medical’s year-end Q4 report for 2025. CEO Hanna Sjöström reflects on a year marked by key milestones as we entered the clinical phase, strengthened the organization, and continued to build on our most strategically important...
Redeye Interview Q2 2025 with CEO Hanna Sjöström
In a new interview with Redeye’s Gustaf Meyer, CEO Hanna Sjöström reflects on Q2 achievements and the road ahead. Redeye also provided a research update, raising their fair value range, now with a base case of SEK 3.3 (3.2). Watch the full interview here: Redeye...
Did you miss Neola Medical’s Q2 2025 report presentation?
Catch up on Neola Medical’s Q2 2025 highlights, including the successful enrollment of the first preterm born baby in the clinical pilot study in Sweden and advancing preparations for the pivotal U.S. clinical study. CEO Hanna Sjöström shares insights into these key...
CEO Hanna Sjöström on Clinical and Strategic Milestones – Redeye Interview Q1 2025
Following a strengthened shareholder base and the first baby enrolled in Neola Medical’s Swedish clinical pilot study, CEO Hanna Sjöström joins Redeye to discuss recent milestones and what lies ahead. She shares insights into the company’s clinical progress, recent...
Stay updated on our progress and milestones
Neola Medical is currently in clinical phase with Neola®. As the company approaches commercial launch, the focus is on securing market authorization in the U.S., followed by Europe.